[Diarrhea and HIV infection].

Area of Science:

• Antiviral Therapy Research
• Gastroenterology
• Infectious Disease Management

Context:

• Highly Active Antiretroviral Therapies (HAART), especially protease inhibitors, have significantly improved HIV replication control.
• Diarrhea remains a common side effect, impacting patient quality of life despite treatment efficacy.
• Infectious causes of diarrhea must be ruled out in general practice.

Purpose:

• To review the incidence, severity, and impact of diarrhea associated with protease inhibitor therapy in HIV patients.
• To assess the effect of diarrhea on antiretroviral treatment adherence and efficacy.
• To recommend management strategies for improving patient quality of life.

Summary:

• Protease inhibitor-associated diarrhea is typically low-grade, often occurring early in treatment, and rarely leads to discontinuation (<2%).
• Diarrhea does not significantly compromise the medium-term efficacy of protease inhibitors in controlling HIV replication.
• Despite minimal impact on efficacy, diarrhea negatively affects patients' quality of life, necessitating management interventions.

Impact:

• Highlights the need for proactive management of diarrhea to enhance patient adherence and well-being.
• Suggests simple therapeutic approaches, including dietary modifications, to mitigate diarrhea incidence and consequences.
• Emphasizes the importance of addressing side effects to optimize long-term HIV management and improve patient outcomes.